A61K 39/12
Viral antigens
A61K39/12 (Viral antigens) appears on 8,011 US grants and 13,136 published applications in this corpus.
Search patents in A61K- Granted patents
- 8,011
- Published applications
- 13,136
- Assignees
- 3,840
- Inventors
- 18,915
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 23 | 0 |
| 1977 | 17 | 0 |
| 1978 | 13 | 0 |
| 1979 | 10 | 0 |
| 1980 | 14 | 0 |
| 1981 | 16 | 0 |
| 1982 | 18 | 0 |
| 1983 | 6 | 0 |
| 1984 | 11 | 0 |
| 1985 | 30 | 0 |
| 1986 | 16 | 0 |
| 1987 | 32 | 0 |
| 1988 | 20 | 0 |
| 1989 | 17 | 0 |
| 1990 | 11 | 0 |
| 1991 | 28 | 0 |
| 1992 | 26 | 0 |
| 1993 | 15 | 0 |
| 1994 | 14 | 0 |
| 1995 | 21 | 0 |
| 1996 | 24 | 0 |
| 1997 | 56 | 0 |
| 1998 | 104 | 0 |
| 1999 | 83 | 0 |
| 2000 | 92 | 0 |
| 2001 | 93 | 33 |
| 2002 | 103 | 142 |
| 2003 | 99 | 230 |
| 2004 | 84 | 293 |
| 2005 | 80 | 273 |
| 2006 | 106 | 270 |
| 2007 | 130 | 280 |
| 2008 | 143 | 333 |
| 2009 | 162 | 396 |
| 2010 | 181 | 500 |
| 2011 | 177 | 470 |
| 2012 | 209 | 446 |
| 2013 | 213 | 446 |
| 2014 | 307 | 515 |
| 2015 | 326 | 527 |
| 2016 | 366 | 565 |
| 2017 | 446 | 590 |
| 2018 | 516 | 612 |
| 2019 | 479 | 691 |
| 2020 | 510 | 703 |
| 2021 | 514 | 763 |
| 2022 | 468 | 821 |
| 2023 | 438 | 962 |
| 2024 | 452 | 978 |
| 2025 | 421 | 767 |
| 2026 | 271 | 530 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Ambient temperature lipid particle storage systems and methods29 Sep 2026US 12,746,281 B2Ambient Biosciences, Inc.
- Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof8 Oct 2026US 2026/0306419 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Pharmaceutical Composition for Vaccination against Cytomegalovirus Infections8 Oct 2026US 2026/0306606 A1Instar Technologies A.S.
- Vaccine Compositions8 Oct 2026US 2026/0306607 A1Seqirus Inc.
- Vaccines against african swine fever virus, and methods of using same8 Oct 2026US 2026/0306608 A1The Wistar Institute of Anatomy and Biology
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Method for processing and preserving collagen-based tissues for transplantation610US 5,336,616 ALifeCell Corporation · 1994
- Method of potentiating an immune response425US 5,075,109 ASouthern Research Institute · 1991
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005